Symbols / PHVS Stock $28.63 +4.91% Pharvaris N.V.

Healthcare • Biotechnology • Switzerland • NMS
PHVS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Exch · Country NMS · Switzerland
Market Cap 1.87B
Enterprise Value 1.49B
Income -175.70M
Sales —
FCF (ttm) -79.09M
Book/sh 4.89
Cash/sh 4.46
Employees 129
Insider 10d —
IPO Feb 05, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E -9.14
PEG —
P/S —
P/B 5.86
P/C —
EV/EBITDA -8.81
EV/Sales —
Quick Ratio 10.01
Current Ratio 10.11
Debt/Eq 0.29
LT Debt/Eq —
EPS (ttm) -3.49
EPS next Y -3.13
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-04-02
ROA -35.81%
ROE -65.19%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 65.41M
Shs Float 35.11M
Insider Own 5.16%
Instit Own 90.69%
Short Float 1.34%
Short Ratio 4.08
Short Interest 712.12K
52W High 30.23
vs 52W High -5.31%
52W Low 14.59
vs 52W Low 96.30%
Beta -2.58
Impl. Vol. 1.08%
Rel Volume 0.96
Avg Volume 160.43K
Volume 154.60K
Target (mean) $46.83
Tgt Median $42.67
Tgt Low $30.16
Tgt High $76.18
# Analysts 13
Recom Strong_buy
Prev Close $27.29
Price $28.63
Change 4.91%
About

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$46.83
Mean price target
2. Current target
$28.63
Latest analyst target
3. DCF / Fair value
$-21.77
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.63
Low
$30.16
High
$76.18
Mean
$46.83

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-09 init Wolfe Research — → Outperform $42
2026-04-07 main Wedbush Outperform → Outperform $42
2026-04-06 main RBC Capital Outperform → Outperform $51
2026-03-09 init RBC Capital — → Outperform $52
2026-03-03 reit HC Wainwright & Co. Buy → Buy $60
2025-12-04 main Oppenheimer Outperform → Outperform $50
2025-12-04 main Guggenheim Buy → Buy $39
2025-12-04 main Morgan Stanley Overweight → Overweight $41
2025-12-04 main B of A Securities Neutral → Neutral $30
2025-12-03 reit HC Wainwright & Co. Buy → Buy $60
2025-11-14 main Morgan Stanley Overweight → Overweight $37
2025-11-13 main Wedbush Outperform → Outperform $30
2025-11-13 reit HC Wainwright & Co. Buy → Buy $60
2025-10-15 init HC Wainwright & Co. — → Buy $60
2025-10-09 up B of A Securities Underperform → Neutral $27
2025-08-13 main JMP Securities Market Outperform → Market Outperform $52
2025-06-05 reit Wedbush Outperform → Outperform $27
2025-05-14 main Cantor Fitzgerald Overweight → Overweight $25
2025-05-14 main Wedbush Outperform → Outperform $27
2025-04-29 init Cantor Fitzgerald — → Overweight $28
News
RSS: Latest PHVS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-16 MODIG BERNDT B.A.E Chief Executive Officer — 2,292 $28.60 $65,559
2026-04-09 MODIG BERNDT B.A.E Chief Executive Officer — 23,333 $27.74 $647,281
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
169.82
+16.57%
145.69
+50.33%
96.91
+11.76%
86.71
Research And Development
124.48
+26.29%
98.56
+50.31%
65.58
+14.29%
57.38
Selling General And Administration
45.34
-3.78%
47.12
+50.37%
31.34
+6.82%
29.34
General And Administrative Expense
45.34
-3.78%
47.12
+50.37%
31.34
+6.82%
29.34
Salaries And Wages
23.14
+22.54%
18.88
+41.83%
13.31
-1.27%
13.48
Other Gand A
22.20
-21.37%
28.24
+56.68%
18.02
+13.69%
15.85
Total Expenses
169.82
+16.57%
145.69
+50.33%
96.91
+11.76%
86.71
Operating Income
-169.82
-16.57%
-145.69
-50.33%
-96.91
-11.76%
-86.71
EBITDA
-169.40
-16.49%
-145.42
-50.45%
-96.66
-11.66%
-86.56
Normalized EBITDA
-159.15
-3.83%
-153.29
-63.88%
-93.54
+4.22%
-97.66
Reconciled Depreciation
0.42
+55.20%
0.27
+4.66%
0.26
+68.40%
0.15
EBIT
-169.82
-16.57%
-145.69
-50.33%
-96.91
-11.76%
-86.71
Total Unusual Items
-10.25
-230.27%
7.87
+352.49%
-3.12
-128.08%
11.10
Total Unusual Items Excluding Goodwill
-10.25
-230.27%
7.87
+352.49%
-3.12
-128.08%
11.10
Net Income
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Pretax Income
-173.71
-31.21%
-132.40
-32.63%
-99.83
-31.95%
-75.65
Net Non Operating Interest Income Expense
6.36
+17.33%
5.42
+2557.87%
0.20
+619.74%
-0.04
Interest Expense Non Operating
—
—
—
0.02
Net Interest Income
6.36
+17.33%
5.42
+2557.87%
0.20
+619.74%
-0.04
Interest Expense
—
—
—
0.02
Other Income Expense
-10.25
-230.27%
7.87
+352.49%
-3.12
-128.08%
11.10
Gain On Sale Of Security
-10.25
-230.27%
7.87
+352.49%
-3.12
-128.08%
11.10
Tax Provision
1.99
+8.92%
1.83
+74.01%
1.05
+54.44%
0.68
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-2.64
-230.27%
2.03
+352.49%
-0.80
-128.08%
2.86
Net Income Including Noncontrolling Interests
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Net Income From Continuing Operation Net Minority Interest
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Net Income From Continuing And Discontinued Operation
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Net Income Continuous Operations
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Normalized Income
-168.09
-20.01%
-140.06
-42.10%
-98.56
-16.55%
-84.57
Net Income Common Stockholders
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Diluted EPS
-2.97
-19.76%
-2.48
+5.70%
-2.63
-15.86%
-2.27
Basic EPS
-2.97
-19.76%
-2.48
+5.70%
-2.63
-15.86%
-2.27
Basic Average Shares
59.16
+9.51%
54.02
+40.71%
38.39
+14.31%
33.59
Diluted Average Shares
59.16
+9.51%
54.02
+40.71%
38.39
+14.31%
33.59
Diluted NI Availto Com Stockholders
-175.70
-30.90%
-134.22
-33.06%
-100.88
-32.15%
-76.33
Insurance And Claims
—
—
6.03
-6.40%
6.44
Total Other Finance Cost
-6.36
-17.33%
-5.42
-2557.87%
-0.20
-619.74%
0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
301.45
+3.46%
291.37
-26.92%
398.69
+137.70%
167.73
Current Assets
299.17
+3.37%
289.42
-27.25%
397.85
+138.45%
166.85
Cash Cash Equivalents And Short Term Investments
291.68
+3.90%
280.73
-28.25%
391.23
+141.74%
161.84
Cash And Cash Equivalents
291.68
+3.90%
280.73
-28.25%
391.23
+141.74%
161.84
Receivables
4.55
+54.56%
2.94
+183.39%
1.04
+171.66%
0.38
Accounts Receivable
—
—
—
0.00
Taxes Receivable
4.55
+54.56%
2.94
+183.39%
1.04
+171.66%
0.38
Prepaid Assets
2.94
-48.87%
5.75
+15.87%
4.96
+22.64%
4.04
Other Current Assets
—
—
0.62
+6.56%
0.58
Total Non Current Assets
2.29
+16.96%
1.96
+131.90%
0.84
-4.87%
0.89
Net PPE
1.40
-5.50%
1.48
+225.05%
0.46
-27.28%
0.63
Gross PPE
1.81
+6.33%
1.70
+192.80%
0.58
-16.04%
0.69
Accumulated Depreciation
-0.41
-85.92%
-0.22
-75.58%
-0.13
-91.33%
-0.07
Other Properties
1.81
+6.33%
1.70
+192.80%
0.58
-16.04%
0.69
Non Current Deferred Assets
0.89
+87.07%
0.47
+22.40%
0.39
+49.16%
0.26
Non Current Deferred Taxes Assets
0.89
+87.07%
0.47
+22.40%
0.39
+49.16%
0.26
Total Liabilities Net Minority Interest
30.18
+27.81%
23.61
+61.23%
14.65
-20.72%
18.47
Current Liabilities
29.60
+28.85%
22.97
+57.34%
14.60
-19.87%
18.22
Payables And Accrued Expenses
17.97
+20.41%
14.93
+75.28%
8.52
-43.48%
15.07
Payables
6.06
+17.26%
5.16
+54.63%
3.34
-53.27%
7.15
Accounts Payable
5.11
+12.08%
4.56
+56.82%
2.91
-51.34%
5.98
Current Accrued Expenses
11.92
+22.08%
9.76
+88.60%
5.18
-34.65%
7.92
Pensionand Other Post Retirement Benefit Plans Current
11.43
+46.06%
7.83
+32.85%
5.89
+98.32%
2.97
Total Tax Payable
0.94
+56.54%
0.60
+39.85%
0.43
-63.17%
1.17
Current Debt And Capital Lease Obligation
0.20
-9.99%
0.22
+13.87%
0.20
+4.24%
0.19
Current Capital Lease Obligation
0.20
-9.99%
0.22
+13.87%
0.20
+4.24%
0.19
Total Non Current Liabilities Net Minority Interest
0.58
-9.77%
0.64
+1366.91%
0.04
-82.53%
0.25
Long Term Debt And Capital Lease Obligation
0.58
-9.77%
0.64
+1366.91%
0.04
-82.53%
0.25
Long Term Capital Lease Obligation
0.58
-9.77%
0.64
+1366.91%
0.04
-82.53%
0.25
Other Non Current Liabilities
—
—
—
—
Stockholders Equity
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Common Stock Equity
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Capital Stock
7.83
+19.92%
6.53
+4.00%
6.27
+54.63%
4.06
Common Stock
7.83
+19.92%
6.53
+4.00%
6.27
+54.63%
4.06
Share Issued
64.96
+19.46%
54.38
+4.00%
52.29
+54.63%
33.82
Ordinary Shares Number
64.96
+19.46%
54.38
+4.00%
52.29
+54.63%
33.82
Additional Paid In Capital
792.55
+27.08%
623.64
+1.27%
615.81
+112.95%
289.18
Retained Earnings
-579.60
-44.09%
-402.26
-51.27%
-265.92
-61.96%
-164.19
Gains Losses Not Affecting Retained Earnings
50.50
+26.72%
39.85
+42.93%
27.88
+37.93%
20.21
Other Equity Adjustments
50.77
+27.84%
39.71
+42.36%
27.89
+38.30%
20.17
Total Equity Gross Minority Interest
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Total Capitalization
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Working Capital
269.56
+1.17%
266.44
-30.48%
383.25
+157.87%
148.62
Invested Capital
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Total Debt
0.78
-9.83%
0.86
+260.59%
0.24
-45.31%
0.44
Capital Lease Obligations
0.78
-9.83%
0.86
+260.59%
0.24
-45.31%
0.44
Net Tangible Assets
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Tangible Book Value
271.27
+1.31%
267.76
-30.28%
384.05
+157.30%
149.26
Foreign Currency Translation Adjustments
-0.27
-296.16%
0.14
+1044.36%
-0.01
-133.69%
0.04
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-137.07
-14.10%
-120.13
-29.10%
-93.05
-38.54%
-67.16
Cash Flow From Continuing Operating Activities
-137.07
-14.10%
-120.13
-29.10%
-93.05
-38.54%
-67.16
Net Income From Continuing Operations
-173.71
-31.21%
-132.40
-32.63%
-99.83
-31.95%
-75.65
Depreciation Amortization Depletion
0.42
+55.20%
0.27
+4.66%
0.26
+68.40%
0.15
Depreciation
0.42
+55.20%
0.27
+4.66%
0.26
+68.40%
0.15
Depreciation And Amortization
0.42
+55.20%
0.27
+4.66%
0.26
+68.40%
0.15
Other Non Cash Items
-0.44
+91.89%
-5.42
-2557.87%
-0.20
-619.74%
0.04
Stock Based Compensation
19.05
+17.53%
16.21
+52.00%
10.66
-6.04%
11.35
Operating Gains Losses
11.74
+260.22%
-7.33
-362.27%
2.79
+125.17%
-11.10
Net Foreign Currency Exchange Gain Loss
11.74
+260.22%
-7.33
-362.27%
2.79
+125.17%
-11.10
Change In Working Capital
7.62
+29.45%
5.89
+200.47%
-5.86
-169.99%
8.38
Change In Receivables
-0.33
-865.55%
-0.03
+16.41%
-0.04
-112.92%
0.32
Change In Payables And Accrued Expense
6.21
+2.47%
6.06
+224.51%
-4.87
-146.05%
10.57
Change In Accrued Expense
6.24
+41.49%
4.41
+733.48%
-0.70
-110.44%
6.66
Change In Payable
-0.03
-101.57%
1.65
+139.63%
-4.17
-206.82%
3.91
Change In Other Current Assets
1.75
+1380.09%
-0.14
+85.71%
-0.95
+62.01%
-2.51
Investing Cash Flow
-0.16
+69.41%
-0.54
-497.98%
-0.09
+27.61%
-0.12
Cash Flow From Continuing Investing Activities
-0.16
+69.41%
-0.54
-497.98%
-0.09
+27.61%
-0.12
Net PPE Purchase And Sale
-0.16
+69.41%
-0.54
-497.98%
-0.09
+27.61%
-0.12
Purchase Of PPE
-0.16
+69.41%
-0.54
-497.98%
-0.09
+27.61%
-0.12
Capital Expenditure
-0.16
+69.41%
-0.54
-497.98%
-0.09
+27.61%
-0.12
Financing Cash Flow
160.61
+5900.52%
2.68
-99.18%
325.39
+3661.61%
8.65
Cash Flow From Continuing Financing Activities
160.61
+5900.52%
2.68
-99.18%
325.39
+3661.61%
8.65
Net Issuance Payments Of Debt
-0.22
-37.18%
-0.16
+27.60%
-0.22
-84.48%
-0.12
Repayment Of Debt
-0.22
-37.18%
-0.16
+27.60%
-0.22
-84.48%
-0.12
Long Term Debt Payments
-0.22
-37.18%
-0.16
+27.60%
-0.22
-84.48%
-0.12
Net Long Term Debt Issuance
-0.22
-37.18%
-0.16
+27.60%
-0.22
-84.48%
-0.12
Net Common Stock Issuance
171.74
+7552.47%
2.24
-99.35%
342.91
+3468.33%
9.61
Net Other Financing Charges
-10.91
-1943.14%
0.59
+103.42%
-17.30
-1959.34%
-0.84
Changes In Cash
23.37
+119.81%
-117.99
-150.80%
232.25
+496.09%
-58.64
Effect Of Exchange Rate Changes
-12.42
-265.84%
7.49
+361.85%
-2.86
-125.71%
11.12
Beginning Cash Position
280.73
-28.25%
391.23
+141.74%
161.84
-22.70%
209.35
End Cash Position
291.68
+3.90%
280.73
-28.25%
391.23
+141.74%
161.84
Free Cash Flow
-137.24
-13.73%
-120.67
-29.56%
-93.14
-38.42%
-67.29
Common Stock Issuance
171.74
+7552.47%
2.24
-99.35%
342.91
+3468.33%
9.61
Interest Paid CFO
—
—
—
-0.14
Interest Received CFO
0.41
-92.42%
5.42
+2185.29%
0.24
—
Issuance Of Capital Stock
171.74
+7552.47%
2.24
-99.35%
342.91
+3468.33%
9.61
Taxes Refund Paid
-2.17
+21.63%
-2.77
-149.66%
-1.11
-506.27%
-0.18
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category